You are here

Interim decisions and invitation for further comment on substances referred to the November 2019 ACMS/ACCS meetings

Scheduling of chemicals and poisons

6 February 2020

This consultation closes on 5 March 2020

Mometasone

An interim decision on mometasone was published on the TGA website 6 June 2019. In accordance with Regulation 42ZCZQ of the Therapeutic Goods Regulations 1990, the delegate of the Secretary has reconsidered the interim decision after seeking advice from the Advisory Committee on Medicines Scheduling in November 2019. This application will proceed to a final decision, which will be published on the TGA website on 23 April 2020.

This web publication constitutes a notice for the purposes of regulation 42ZCZP of the Therapeutic Goods Regulations 1990 (the Regulations). In accordance with regulation 42ZCZP, this notice sets out:

  • the interim decisions made by a delegate of the Secretary under regulation 42ZCZN in relation to proposed amendments to the current Poisons Standard which were referred to an expert advisory committee under subdivision 3D.2 of the Regulations in November 2019;
  • the proposed date of effect of the proposed amendments (in circumstances where the interim decision proposes an amendment to the current Poisons Standard).

In accordance with regulation 42ZCZP, interested persons (including the applicant requesting the amendment) are invited to make submissions to the Secretary in relation to these interim decisions on or before 5 March 2020.

Persons making submissions are strongly encouraged to lodge submissions in an electronic format (word or unsecured PDF preferred) using the public submission coversheet available on the TGA's website. Where possible, submissions should be sent to the email address provided below:

  • medicines.scheduling@health.gov.au (for submissions relating to interim decisions made in relation to proposed amendments referred to the Advisory Committee on Medicines Scheduling or the Advisory Committee on Medicines and Chemicals Scheduling in joint session).

Please note that in accordance with sub-regulation 42ZCZQ(4) of the Regulations, the Secretary must publish all relevant submissions received, unless the Secretary considers the information to be confidential information.

Interim decisions and invitation for further comment on substances referred to the November 2019 ACMS/ACCS meetings

How to access a pdf or Word document

*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open it from there.

We aim to provide documents in an accessible format. If you're having problems using this document, please contact medicines.scheduling@health.gov.au (for substances referred to the ACMS or Joint ACCS-ACMS) or chemicals.scheduling@health.gov.au (for substances referred to the ACCS).

Contents

  1. Interim decisions on proposed amendments referred to the Advisory Committee on Medicines Scheduling (ACMS #28, November 2019)
    • 1.1. Interim decision in relation to sumatriptan
    • 1.2. Interim decision in relation to zolmitriptan
    • 1.3. Interim decision in relation to calcifediol
    • 1.4. Interim decision in relation to paracetamol (liquid formulations)
    • 1.5. Interim decision in relation to Paracetamol + ibuprofen
    • 1.6. Interim decision in relation to hyoscine butylbromide
    • 1.7. Interim decision in relation to Lidocaine
  2. Interim decisions on proposed amendments referred to the Advisory Committee on Chemicals Scheduling (ACCS #26, November 2019)
    • 2.1. Interim decision in relation to carbon monoxide
    • 2.2. Interim decision in relation to momfluorothrin
    • 2.3. Interim decision in relation to tetraniliprole
    • 2.4. Interim decision in relation to methiozolin
    • 2.5. Interim decision in relation to lambda-cyhalothrin
  3. Interim decision on proposed amendment referred to the Advisory Committee on Medicines and Chemicals Scheduling in joint session (Joint ACCS/ACMS #23, November 2019)
    • 3.1. Interim decision in relation to caffeine
    • 3.2. Interim decision in relation to N-methyl-2-pyrrolidone (NMP)